Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | FYN | P06241 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 5/20 | 0.32 |
| ▸ | CNR2 | P34972 | 4/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6104555 | 0.87 | ATM (0.40) | MAPTTP53FYNKDM4EALDH1A1 | |
| SCHEMBL6105090 | 0.86 | TP53 (0.47) | MAPTTP53FYNKDM4EALDH1A1 | |
| SCHEMBL5453415 | 0.86 | MAPT (0.36) | MAPTTP53FYNALDH1A1GAA | |
| SCHEMBL5453422 | 0.86 | MAPT (0.36) | MAPTTP53FYNALDH1A1GAA | |
| SCHEMBL5459554 | 0.83 | ALOX5 (0.42) | MAPTTP53FYNKDM4EALDH1A1 | |
| SCHEMBL6106788 | 0.82 | ALDH1A1 (0.38) | MAPTTP53FYNKDM4EALDH1A1 | |
| SCHEMBL5212848 | 0.82 | GAA (0.40) | MAPTFYNKDM4EALDH1A1GAA | |
| SCHEMBL5457446 | 0.81 | MAPK14 (0.36) | KDM4EALDH1A1RAB9ANPC1RXFP1 | |
| SCHEMBL6105851 | 0.81 | MAPT (0.42) | MAPTTP53ALDH1A1RAB9ACNR1 | |
| SCHEMBL5212553 | 0.79 | GAA (0.42) | FYNGAAPDE4BATMMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070287721-A1 | Pyrazolopyridinyl pyridine | BOYD F LESLIE | 2007-12-13 | — | — | US | disclosed |
| US-7153855-B2 | Pyrazolopyridinyl pyrimidine therapeutic compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2006-12-26 | — | — | US | disclosed |
| EP-1377573-B1 | PYRAZOLOPYRIDINE DERIVATIVES | GLAXO GROUP LTD (GB) | 2005-07-27 | — | — | EP | disclosed |
| US-20050049260-A1 | Therapeutic compounds | SMITHKLINE BEECHAM CORPORATION | 2005-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287721-A1 | Pyrazolopyridinyl pyridine | CYP3A5, CYP2C19, CYP3A4 | MAPT 1659/4885TP53 1396/4885FYN 929/4885 |
| US-20050049260-A1 | Therapeutic compounds | ABCB1, PCSK9, ABCB11 | MAPT 696/4885TP53 3084/4885FYN 1889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.